These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2718144)

  • 1. Kudos to the Food and Drug Administration: reversal of the package insert warning for birth defects for oral contraceptives.
    Brent RL
    Teratology; 1989 Jan; 39(1):93-4. PubMed ID: 2718144
    [No Abstract]   [Full Text] [Related]  

  • 2. In brief: FDA warning about drospirenone in oral contraceptives.
    Med Lett Drugs Ther; 2012 Apr; 54(1389):33. PubMed ID: 22538620
    [No Abstract]   [Full Text] [Related]  

  • 3. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription drug products that require patient package inserts; ampicillin and phenytoin--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28. PubMed ID: 10249520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of oral contraceptives related to steroid content: a critical review.
    Sturtevant FM
    Int J Fertil; 1989; 34(5):323-32. PubMed ID: 2571592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progestational drug products for human use; requirements for labeling directed to the patient. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Nov; 64(220):62110-2. PubMed ID: 11010691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration.
    Kelsey FO
    Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617
    [No Abstract]   [Full Text] [Related]  

  • 8. Proposed NSAID package insert labeling.
    Food and Drug Administration U.S. Public Health Service
    J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug use, the package insert, and the practice of medicine.
    Roth SH
    Arch Intern Med; 1982 May; 142(5):871-2. PubMed ID: 7082110
    [No Abstract]   [Full Text] [Related]  

  • 10. The medicolegal significance of the package insert.
    Hirsh HL
    Conn Med; 1978 Dec; 42(12):785-8. PubMed ID: 720048
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient package inserts: a research perspective.
    Morris LA; Groft SC
    Drug Ther; 1982; ():191-217. PubMed ID: 7105993
    [No Abstract]   [Full Text] [Related]  

  • 12. Natazia--a new oral contraceptive.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):71-2. PubMed ID: 20814403
    [No Abstract]   [Full Text] [Related]  

  • 13. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The medicolegal significance of the package insert.
    Hirsh HL
    Med Trial Tech Q; 1976; 23(2):143-50. PubMed ID: 1004155
    [No Abstract]   [Full Text] [Related]  

  • 15. The medicolegal significance of the package insert.
    Hirsh HL
    J Fam Pract; 1977 Jun; 4(6):1141-3. PubMed ID: 874441
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral contraception and some debatable side effects.
    Astedt B
    Acta Obstet Gynecol Scand Suppl; 1982; 105():17-23. PubMed ID: 7044021
    [No Abstract]   [Full Text] [Related]  

  • 17. Package insert-stuffer, guide or autocrat?
    Can Med Assoc J; 1968 Aug 24-31; 99(8):377-9. PubMed ID: 4952400
    [No Abstract]   [Full Text] [Related]  

  • 18. The practice of anesthesiology and the package insert: decision-making regarding drug use in anesthesiology.
    White PF; Watcha MF
    Anesth Analg; 1993 May; 76(5):928-30. PubMed ID: 8484546
    [No Abstract]   [Full Text] [Related]  

  • 19. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation.
    Brent RL
    Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):906-18. PubMed ID: 16206282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription drug products; revocation of patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1982 Sep; 47(173):39147-55. PubMed ID: 10258154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.